Slide 1: Annual General Meeting 2019
W’ ‘ Annval 7201 9 — Re. ViroGates*’
Slide 2: Dagsorden
ViroGates Company presentation 2019 2 Dagsorden 1. Valg af dirigent Election of chairman of the meeting 2. Bestyrelsens beretning om selskabets virksomhed i det forløbne år The board’s report on the company’s business in the past year 3. Fremlæggelse af årsrapport med revisionspåtegning til godkende
Slide 3: Dr. Lars Kongsbak, Chairman ViroGates A/S
ViroGates Company presentation 2019 3 Dr. Lars Kongsbak, Chairman ViroGates A/S
Slide 4: Major achievements 2018
ViroGates Company presentation 2019 4 Major achievements 2018 March June July Commercial organization IPO at Nasdaq OMX First North ViroGates announced its first strengthened with VP Sales Denmark raising gross proceeds international paying customer for the use & Marketing responsible for of DKK 75m
Slide 5: Sales, EBITDA and Cash flow
ViroGates Company presentation 2019 5 Sales, EBITDA and Cash flow Financial highlights and key ratios 2018 DKK (‘000) unless otherwise stated 2018 2017 2016 2015 2014 Net revenue DKK (‘000) Income statement 3,592 3,686 3,104 3,316 Net revenue 3,316 2,441 3,686 3,592 3,104 Operating profit/loss -18,1
Slide 6: Clinical data
ViroGates Company presentation 2019 6 Clinical data
Slide 7: Significant savings potential in acute care
ViroGates Company presentation 2019 7 Significant savings potential in acute care Huge savings potential in Acute Care EURm 870.0 368.0 293.0 243.0 87.0 112.4 82.4 91.0 63.3 51.6 29.0 7.8 Denmark Germany Spain Italy France Poland Cost of using suPARnostic® Net healthcare savings Source: Average cost
Slide 8: How to use suPARnostic in the patient flow
ViroGates Company presentation 2019 8 How to use suPARnostic® in the patient flow Personal walk in Ambulance General Practitioner Triaging Emergency of patients Department 56% 32% 12% of patients of patients of patients suPAR ≤3ng/ml suPAR 3-6ng/ml suPAR ≥6ng/ml Little risk of life- Diseased patient
Slide 9: Operational Update
ViroGates Company presentation 2019 9 Operational Update Work Idea Plan Goal
Slide 10: Listing on Nasdaq First North CPH
ViroGates Company presentation 2019 10 Listing on Nasdaq First North CPH • Listed on NASDAQ First North CPH On 26/6 2018 • Ticker ”VIRO” (ISIN: DK0061030574). • Gross proceeds raised: 75 million DKK
Slide 11: Market potential and development
ViroGates Company presentation 2019 11 Market potential and development Post acute GP Physicians Private Health test Acute Care EURm care Europe 240 99 North America 210 87 19 billion Euro 27 billion Euro market market opportunity opportunity RoW 600 497 Health screens and regular visits Private Hea
Slide 12: Conference attendance with booth
ViroGates Company presentation 2019 12 Conference attendance with booth Conferences attended with booth/visual presence • DASEM • DECM • EMS Copenhagen • SEMES Alicante (Spain) • EUSEM • ACC – Acute Cardiovascular conf. • MEDICA
Slide 13: Case Study: Spain
ViroGates Company presentation 2019 13 Case Study: Spain 11 12 suPARnostic® is currently 10 being used in hospitals in: 1 Villarrobledo 2 2 Valladolid 9 3 Sanchinarro (Madrid) 6 8 4 4 Torrejon 3 5 13 5 Mostoles 14 6 La Moraleja (Madrid) 1 7 Tenerife 8 Moncloa (Madrid) 9 Tarragona 10 Burgos 11 Bilbao
Slide 14: Product offering/development
ViroGates Company presentation 2019 14 Product offering/development suPARnostic® suPARnostic® suPARnostic® Product AUTO Flex ELISA Quick Triage TurbiLatex Detection platform Automated, centralized Application R&D use & clinical lab Near patient use laboratory Immuno-detection ELISA Lateral flow Turb
Slide 15: Turbidimetry Development Project
ViroGates Company presentation 2019 15 Turbidimetry Development Project suPARnostic® automated • Turbidimetric products are by far the most used products in the immuno-chemical area • Millions of analysis are run annually in a mid-size hospital • Requires no hands on handling after blood is drawn •
Slide 16: Product Packaging
ViroGates Company presentation 2019 16 Product Packaging suPARnostic® TurbiLatex Abbott Architect • Packed in Universal Bottles • And customised to individual needs Roche Cobas 501/502 i.e. (Roche Modular Systems 6000 & 8000) Final Product suPARnostic® Turbilatex Siemens Advia Centaur
Slide 17: A best in class Point of Care solution for suPARnostic
ViroGates Company presentation 2019 17 A best in class Point of Care solution for suPARnostic® GenSpeed • A simple and fast finger-prick blood test for market expansion • Health screening – CRP, suPAR • Pre-hospital settings (in- ambulance or in home, e.g. PRIUS study) – bundle with CRP and lactate
Slide 18: Expanding the market reach and segments
ViroGates Company presentation 2019 18 Expanding the market reach and segments Ambulance transport Acute (17 mio Emergency transports in EU) 340 m Euro Potential for GENSPEED In hospital/acute care General Practitioners segment 1 bn Euro 19 bn Euro Potential for Turbilatex/QT/GENSPEED Potential for
Slide 19: Major goals going forward
ViroGates Company presentation 2019 19 Major goals going forward 40 40 Clinical customers in 2020 Break even Cash flow break even in 2020 Platforms Development of products for Abbott, Siemens GENSPEED Development of Point of Care and Beckman Coulter platforms GENSPEED product
Slide 20: Sales, EBITDA and Cash flow
ViroGates Company presentation 2019 20 Sales, EBITDA and Cash flow Financial highlights and key ratios 2018 DKK (‘000) unless otherwise stated 2018 2017 2016 2015 2014 Net revenue DKK (‘000) Income statement 3,592 3,686 3,104 3,316 Net revenue 3,316 2,441 3,686 3,592 3,104 Operating profit/loss -18,
Slide 21: Non executive board
ViroGates Company presentation 2019 21 Non executive board Dr. Lars Kongsbak Bernd Uder Dr. Jørgen Thorball Lars Krogsgaard Chairman Co-founder 25+ years operational 25+ years operational 25+ years experience in life 25+ years experience in experience in life science experience in life science scien
Slide 22: Election of auditor
ViroGates Company presentation 2019 22 Election of auditor The board propose to reelect BDO Statsautoriseret revisionsaktieselskab Jesper Buch CVR no. 20222670 Partner, statsautoriseret revisor København
Slide 23: Any other business
ViroGates Company presentation 2019 23 Any other business
Slide 24: Thank you very much for your attendance!
ViroGates Company presentation 2019 24 Thank you very much for your attendance!